论文部分内容阅读
目的分析研究组织因子途径抑制物-2(TFPI-2)在宫颈癌组织中表达。方法应用免疫组化方法检测50例宫颈癌、50例CIN和15例正常宫颈组织中TFPI-2蛋白的表达,并探讨其与宫颈癌临床期别、病理分级及淋巴结转移等关系。结果正常宫颈组织、宫颈上皮内瘤变(CIN)和宫颈癌中TFPI-2表达逐渐降低,三者间比较差异有统计学意义(P<0.01)。宫颈癌组织中TFPI-2表达水平与宫颈癌的FIGO分期及淋巴结转移有关,差异有统计学意义(P<0.05)。但是与宫颈癌的分化程度及病理类型之间差异无统计学意义(P>0.05)。结论 TFPI-2的表达减少可能是宫颈癌发生发展的机制之一,TTFPI-2表达下调与宫颈癌的不良预后相关。
Objective To investigate the expression of tissue factor pathway inhibitor-2 (TFPI-2) in cervical cancer. Methods The expressions of TFPI-2 protein in 50 cases of cervical cancer, 50 cases of CIN and 15 cases of normal cervical tissue were detected by immunohistochemistry. The relationship between TFPI-2 protein and the clinical stage, pathological grade and lymph node metastasis of cervical cancer was also explored. Results The expression of TFPI-2 in normal cervical tissue, cervical intraepithelial neoplasia (CIN) and cervical cancer gradually decreased, with significant difference between the three groups (P <0.01). The expression of TFPI-2 in cervical cancer was correlated with the FIGO staging and lymph node metastasis of cervical cancer, the difference was statistically significant (P <0.05). However, there was no significant difference between cervical cancer differentiation and pathological type (P> 0.05). Conclusion The decreased expression of TFPI-2 may be one of the mechanisms of cervical carcinogenesis. The down-regulation of TTFPI-2 is associated with poor prognosis of cervical cancer.